Display Settings:

Format

Send to:

Choose Destination
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):321-5. doi: 10.1016/j.clml.2011.03.021. Epub 2011 May 7.

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.

Author information

  • 1Institute of Hematology and Medical Oncology "L. e A. Ser√†gnoli," University of Bologna, Bologna, Italy.

Abstract

BACKGROUND:

We performed a retrospective investigation to assess the efficacy of chemotherapy and rituximab as front-line treatment for primary bone lymphoma (PBL).

PATIENTS AND METHODS:

Between 1999 and 2009, 21 previously untreated patients received a diagnosis of PBL. All the patients were treated with anthracycline-containing chemotherapeutic regimens, with the addition of rituximab; 11 patients received consolidative radiation therapy after induction treatment.

RESULTS:

Patients' median age was 34 years (range, 18-82 years); all presented with diffuse large B-cell lymphoma. Complete responses were seen in 95.2% of the patients treated. No relapses were observed at a median follow-up of 43.9 months. Eight-year overall survival and disease-free survival were 95.2% and 100.0%, respectively.

CONCLUSION:

These data indicate that the combined chemotherapy plus rituximab treatment may represent a suitable front-line approach in PBL, with a high rate of responses and an excellent long-term survival.

Copyright © 2011. Published by Elsevier Inc.

PMID:
21816370
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk